Abstract
We read with interest the results of the trial “Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer” published in NEJM. The authors should be congratulated for their efforts to organize and manage this large multicenter trial. In fact, in the surgical-oncology field, there are several examples when a study is conducted with the aim to demonstrate a "maintained oncological efficacy" using a "less destructive intervention". We believe that the dream of all thoracic surgeons is to be able to go down the same road that breast surgeons took when they abandoned mastectomy in favor of quadrantectomy. We fear that the time is yet to come, and who knows when it will ever be due to epidemiologic variability of lung cancer or the introduction of new and more effective systemic therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
